March 19, 2018 / 11:16 AM / 3 months ago

BRIEF-Resverlogix Exceeds Full Enrollment For The Pivotal Phase 3 Betonmace Clinical Trial

March 19 (Reuters) - Resverlogix Corp:

* RESVERLOGIX EXCEEDS FULL ENROLLMENT FOR THE PIVOTAL PHASE 3 BETONMACE CLINICAL TRIAL

* RESVERLOGIX CORP - EXPLORING OPTION OF US ENROLLMENT IN BETONMACE TRIAL AS WELL AS OPTION OF RELYING ON EXISTING BETONMACE DATA TO FILE A US NDA

* RESVERLOGIX CORP - ‍ PRIMARY ENDPOINT READ-OUT OF ONGOING PHASE 3 BETONMACE TRIAL AROUND END OF 2018​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below